510 (k) Summary

Summary of 510 (k) safety and effectiveness information upon which the substantial equivalence determination is based:

Prepared: September 13, 2003
Applicant: Futura Biomedical
990 Park Center Drive
Vista, CA 92081
Telephone: 760-599-1670
Fax: 760-599-1675
Contact: Louise M. Focht

Device Name: Subtalar Arthrorisis Implant
Device Trade Name: Subtalar Arthrorisis Implant
Device Classification: Class II
Reviewing Panel: Orthopedic
Regulation Number: 888.3040
Product Code: 87 HWC
Predicate Device: K001231 – The New Deal Kalix Implant
Registration Number: 2030833
Owner Operator Number: 9028319

Device Description:

The Futura Biomedical Implant is a one-piece device made of Titanium (6AL-4V ELI) intended to be implanted into the sinus tarsi of the foot. The implant is designed in 6 sizes. The implant which is used in the treatment of excessive motion of the talus relative to the calcaneus acts as a spacer for the joint, maintaining the joint space, allowing for range of motion, but limiting excessive pronation.

Indications for Use:

The Futura Biomedical Arthrorisis Implant is intended to treat hyperpronated foot and stabilize the subtalar joint. It is intended to block forward, downward and medial displacement of the talus, thus allowing normal subtalar joint motion but blocking excessive pronation and the resulting sequela. Examples include:

Flat foot treatment in children and adolescents
Congenital flat foot
Unsuccessful long term orthopaedic treatment (shoes, insoles...)
Tarsal coalitions
Painful flat foot
Supple deformity in posterior tibial tendon dysfunction
Paralytic flat foot
Subtalar instability

Comparison to Predicate Device:

The legally marketed predicate device to which this device is substantially equivalent is the New Deal Kalix Implant.

Regulatory Class: II
Product Code: 87 KXE

Table 1. Comparison of Futura Biomedical and New Deal Kalix Implant

<table>
<thead>
<tr>
<th>Item</th>
<th>Futura Product</th>
<th>New Deal Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name</td>
<td>Subtalar Arthrorisis Implant</td>
<td>Subtalar Arthrorisisss Implant</td>
</tr>
<tr>
<td>Use</td>
<td>Single use</td>
<td>Single use</td>
</tr>
<tr>
<td>Fixation</td>
<td>Screw</td>
<td>Screw</td>
</tr>
<tr>
<td>Constraint</td>
<td>Non constrained</td>
<td>non constrained</td>
</tr>
<tr>
<td>Material</td>
<td>Titanium 6AL-4V ELI</td>
<td>Titanium alloy and UHMWPE</td>
</tr>
<tr>
<td>Sizes</td>
<td>6 sizes</td>
<td>5 sizes</td>
</tr>
<tr>
<td>Indications for use</td>
<td>The Futura Biomedical Arthrorisis Implant is intended to treat hyperpronated foot and stabilize the subtalar joint. It is intended to block forward, downward and medial displacement of the talus, thus allowing normal subtalar joint motion but blocking excessive pronation and the resulting sequela. Examples include: Flat foot treatment in children and adolescents Congenital flat foot Unsuccessful long term orthopaedic treatment (shoes, insoles...) Tarsal coalitions Painful flat foot Supple deformity in posterior tibial tendon dysfunction Paralytic flat foot Subtalar instability</td>
<td>The New Deal Kalix implant is intended to treat hyperpronated foot and stabilize the subtalar joint. It is intended to block forward, downward and medial displacement of the talus, thus allowing normal subtalar joint motion but blocking excessive pronation and the resulting sequela. Examples include: Flat foot treatment in children and adolescents Congenital flat foot Unsuccessful long term orthopaedic treatment (shoes, insoles...) Tarsal coalitions Painful flat foot Supple deformity in posterior tibial tendon dysfunction Paralytic flat foot Subtalar instability</td>
</tr>
</tbody>
</table>
Similarities of the Futura Biomedical Subtalar Arthrosis Implant and the New Deal Kalix Implant include:

Both devices are: intended for single use only; intended for surgical implantation longer than 30 days; both devices are placed into the sinus tarsi of the foot, allowing normal subtalar joint motion while blocking excessive pronation and resulting sequela; both devices are made of industry standard materials, no new materials are introduced in either product; Both devices are comparably sized; both devices have the same indications for use.

Summary:

The device and the predicate device have similar design characteristics and intended use. The new device is substantially equivalent to the predicate device.
Ms. Louise M. Focht
Futura Biomedical
990 Park Center Drive, Suite H
Vista, California 92081

Re: K032902
Trade/Device Name: Subtalar Arthrosis Implant
Regulation Number: 21 CFR 888.3040
Regulation Name: Smooth or threaded metallic bone fixation fastener
Regulatory Class: II
Product Code: HWC
Dated: September 16, 2003
Received: September 17, 2003

Dear Ms. Focht:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use:

The Futura Biomedical Arthrosis Implant is intended to treat hyperpronated foot and stabilize the subtalar joint. It is intended to block forward, downward and medial displacement of the talus, thus allowing normal subtalar joint motion but blocking excessive pronation and the resulting sequela. Examples include:

- Flat foot treatment in children and adolescents
- Congenital flat foot
- Unsuccessful long term orthopaedic treatment (shoes, insoles…)
- Tarsal coalitions
- Painful flat foot
- Supple deformity in posterior tibial tendon dysfunction
- Paralytic flat foot
- Subtalar instability

Prescription Use _X_ AND/OR Over-The-Counter Use

(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)